These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 28244558)

  • 1. Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models.
    O'Caoimh R; Igras E; Ramesh A; Power B; O'Connor K; Liston R
    J Frailty Aging; 2017; 6(1):46-52. PubMed ID: 28244558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study.
    Lefebvre MC; St-Onge M; Glazer-Cavanagh M; Bell L; Kha Nguyen JN; Viet-Quoc Nguyen P; Tannenbaum C
    Can J Cardiol; 2016 Feb; 32(2):169-76. PubMed ID: 26277091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
    Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
    Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
    Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
    Shantsila E; Wolff A; Lip GY; Lane DA
    Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CHA
    Pundi K; Perino AC; Fan J; Din N; Szummer K; Heidenreich P; Turakhia MP
    Am Heart J; 2023 Jul; 261():85-94. PubMed ID: 37024025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HAS-BLED and HAS-BED Versus CHADS
    Poli D; Antonucci E; Pengo V; Testa S; Palareti G
    Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study.
    Zweiker D; Zweiker R; Winkler E; Roesch K; Schumacher M; Stepan V; Krippl P; Bauer N; Heine M; Reicht G; Zweiker G; Sprenger M; Watzinger N
    BMJ Open; 2017 Sep; 7(9):e018242. PubMed ID: 28951417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.
    Polo García J; Vargas Ortega D; Formiga F; Unzueta I; Fernández de Cabo S; Chaves J
    Semergen; 2019 Sep; 45(6):396-405. PubMed ID: 30573367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.
    Kim D; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Stroke; 2022 Jun; 53(6):1873-1882. PubMed ID: 35109686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk.
    Mascarenhas DAN; Sharma M; Ziegler PD; Kantharia BK
    Acta Cardiol; 2019 Apr; 74(2):131-139. PubMed ID: 29863432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.